Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Parexel Intl Cp (PRXL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,502,650
  • Shares Outstanding, K 51,120
  • Annual Sales, $ 2,442 M
  • Annual Income, $ 107,300 K
  • 36-Month Beta 0.79
  • Price/Sales 1.84
  • Price/Cash Flow 16.08
  • Price/Book 7.09
  • Price/Earnings ttm 26.14
  • Earnings Per Share ttm 3.37
  • Most Recent Earnings 0.74 on 05/03/17
  • Next Earnings Date 10/25/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/17
See More
  • Average Estimate 0.89
  • Number of Estimates 8
  • High Estimate 0.96
  • Low Estimate 0.82
  • Prior Year 0.76
  • Growth Rate Est. (year over year) +17.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.69 +0.44%
on 09/07/17
88.10 -0.02%
on 09/29/17
+0.30 (+0.34%)
since 08/29/17
3-Month
86.85 +1.42%
on 06/30/17
88.10 -0.02%
on 09/29/17
+1.18 (+1.36%)
since 06/29/17
52-Week
51.16 +72.17%
on 11/11/16
88.10 -0.02%
on 09/29/17
+19.58 (+28.58%)
since 09/29/16

Most Recent Stories

More News
PAREXEL Announces Several New Patient-Centric Innovations to Address Drug Development Challenges

PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced that it has developed several new solutions that take a patient-centric approach...

PRXL : 88.08 (-0.02%)
PAREXEL and Datavant Partner to Deliver Advanced Data and Real-World Evidence Analytics to Enhance Drug Development and Commercialization

PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, and Datavant, Inc., a healthcare technology company focused on enabling the secure de-identification...

PRXL : 88.08 (-0.02%)
PAREXEL Advances Patient-Centric Drug Development with Introduction of Its Patient Innovation Center

PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced the launch of its Patient Innovation Center, designed to help guide sponsors in...

PRXL : 88.08 (-0.02%)
PAREXEL Announces Appointment of Two Key Executives

PAREXEL International Corporation, the world's leading innovator of biopharmaceutical services, today announced the appointment of Greg Rush as Executive Vice President and Chief Financial...

PRXL : 88.08 (-0.02%)
PAREXEL's Xavier Flinois Named to 2018 PharmaVOICE 100

PAREXEL International Corporation, the world's leading innovator of biopharmaceutical services, today announced that Xavier Flinois, President of PAREXEL Informatics, has been named to PharmaVOICE...

PRXL : 88.08 (-0.02%)
PAREXEL Co-Founder and Board Chairman Josef von Rickenbach Receives 2018 Ellis Island Medal of Honor

PAREXEL International Corporation, the world's leading innovator of biopharmaceutical services, announced today that Josef von Rickenbach, PAREXEL co-founder and Chairman of the Board of...

PRXL : 88.08 (-0.02%)
PAREXEL Announces Appointment of Peyton Howell as Chief Commercial and Strategy Officer

PAREXEL International Corporation, the world's leading innovator of biopharmaceutical services, today announced the appointment of Peyton Howell as Chief Commercial and Strategy Officer,...

ABC : 89.54 (+1.20%)
PRXL : 88.08 (-0.02%)
PAREXEL's Randomization and Trial Supply Management Service Recognized as Leader in Second Consecutive Industry Standard Research Benchmark Report

PAREXEL International Corporation, the world's leading innovator of biopharmaceutical services, announced today that for the second time, its randomization and trial supply management (RTSM)...

PRXL : 88.08 (-0.02%)
PAREXEL and Meiji Pharmaceutical University Announce Academic Program to Develop Japan's Biopharmaceutical Workforce

PAREXEL International Corporation, the world's leading innovator of biopharmaceutical services, and Meiji Pharmaceutical University (MPU), a private pharmacy and science university, today...

PRXL : 88.08 (-0.02%)
PAREXEL Introduces Integrated Medical Writing Solutions Service Offering

PAREXEL International Corporation, the world's leading innovator of biopharmaceutical services, today introduced PAREXEL's Medical Writing Solutions, a newly integrated, end-to-end offering...

PRXL : 88.08 (-0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade PRXL with:

Business Summary

Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With...

See More

Key Turning Points

2nd Resistance Point 88.11
1st Resistance Point 88.10
Last Price 88.08
1st Support Level 88.07
2nd Support Level 88.05

See More

52-Week High 88.10
Last Price 88.08
Fibonacci 61.8% 73.99
Fibonacci 50% 69.63
Fibonacci 38.2% 65.27
52-Week Low 51.16

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar